Feature Comera working to transform biologics to SQ injections from IV delivery Comera Life Sciences (NASDAQ:CMRA) is using a proprietary excipient formulation platform, known as SQore, to potentially transform intravenous (IV) biologics into subcutaneous (SQ) versions that patients can self... November 1, 2022